Fractyl Health, Inc. Common Stock (GUTS)vsInsmed Inc (INSM)
GUTS
Fractyl Health, Inc. Common Stock
$0.50
+16.17%
HEALTHCARE · Cap: $67.68M
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 20214000% more annual revenue ($606.42M vs $3,000). GUTS leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
GUTS
Avoid26
out of 100
Grade: F
INSM
Hold39
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
No standout strengths identified
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -5.2% — below average capital efficiency
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : GUTS
The strongest argument for GUTS centers on Debt/Equity.
Bull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bear Case : GUTS
The primary concerns for GUTS are EPS Growth, Market Cap, Profit Margin.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Key Dynamics to Monitor
GUTS profiles as a value stock while INSM is a turnaround play — different risk/reward profiles.
GUTS carries more volatility with a beta of 1.51 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
GUTS generates stronger free cash flow (-23M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 26/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Fractyl Health, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company is headquartered in Lexington, Massachusetts.
Visit Website →Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?